

my Pharma

by Veritas

Advanced pharmacogenomic test based on clinical guidelines.



It has been estimated that genetics may account for 20–95% of variability in drug disposition and effects in the organism¹

Genetic variants in certain genes may impact the persons' ability to metabolize specific drugs, increasing or decreasing the efficacy or exposing the patient to adverse events.

What is myPharma?

It is a pharmacogenomic test based on international clinical guidelines to adapt the patient drug prescription based on the genetic makeup. It is clinically useful for many medical areas.

What does the test include?

Comprehensive report including the analysis of specific variants in 25 genes related to the metabolism, efficacy or toxicity of 129 active ingredients. The report includes brief recommendations based on clinical guidelines.

Who is it for?

myPharma is for everyone. The genetic analysis is performed once in a lifetime, and it is useful for both current and future drug prescription. It is particularly indicated for patients on multiple medications.

*CPIC: Clinical Pharmacogenetics Implementation Consortium

**DPWG: Dutch Pharmacogenetics Working Group

Why prescribe myPharma?

The test provides relevant information to adapt medical prescription in order to:

- Reduce or avoid adverse effects of medication.
- Select the most effective medication and dosage for each patient.
- Reduce time and resources finding the most appropriate medication for the patient.
- Provide a lifetime personalized drug prescription.

Based on most relevant guidelines

myPharma has been developed according to the most updated international pharmacogenomic guidelines such as CPIC* or DPWG**. Only genes and medications with high level of evidence are included in the report.

What is the sample type?

Saliva or blood sample in a kit provided by Veritas.

The percentage of hospital admissions due to adverse drug reactions is around 3.5%.²

Genes included on myPharma

myPharma is based on whole exome sequencing (WES) and the subsequent analysis of specific variants in the following genes:

<i>ABCG2</i>	<i>CYP3A5</i>	<i>HLA-DRB1</i>
<i>ADRB2</i>	<i>CYP4F2</i>	<i>IFNL3</i>
<i>CACNA1S</i>	<i>DPYD</i>	<i>MT-RNR1</i>
<i>CYP2B6</i>	<i>F2 F5</i>	<i>NAT2</i>
<i>CYP2C19</i>	<i>G6PD</i>	<i>NUDT15</i>
<i>CYP2C9</i>	<i>HLA-A</i>	<i>SLCO1B1</i>
<i>CYP2D6</i>	<i>HLA-B</i>	<i>TPMT</i>
<i>CYP3A4</i>	<i>HLA-DQA1</i>	<i>UGT1A1</i>

Average percentage of patients for whom a certain type of drug is ineffective

Antidepressants (SSRIs)



Oncology



1. Evans WE, McLeod HL. Pharmacogenomics — Drug Disposition, Drug Targets, and Side Effects. N Engl J Med. 2003;348(6):538-49.

2. Bouvy JC, De Bruin ML, Koopmanschap MA. Epidemiology of Adverse Drug Reactions in Europe: A Review of Recent Observational Studies. Drug Saf. 2015;38(5):437-53.

3. Spear BB, Heath-Chiozzi M, Huff J. Clinical application of pharmacogenetics. Trends Mol Med. 2001;7(5):201-4.

myPharma through life



Pain Medicine: Ibuprofen

Clinical manifestation: Moderate pain / fever

Drug prescription: Ibuprofen

Gene involved: *CYP2C9* *2/*6

Phenotype: Poor metabolizer

Poor metabolizer
Risk of adverse events

Reduce dose

Intermediate
metabolizer

**Reduce dose /
Label dosage ***

Normal
metabolizer

Label dosage

* The recommendations for intermediate metabolizers depend on the activity score.



Psychiatry: Paroxetine

Clinical manifestation: Anxiety / Depression

Drug prescription: Paroxetine

Gene involved: *CYP2D6* *1/*1x2

Phenotype: Ultrarapid metabolizer

Poor metabolizer
Risk of adverse events

Reduce dose

Normal
metabolizer

Label dosage

Ultrarapid metabolizer
Risk of therapeutic failure

**Alternative agent
(e.g. Citalopram)**



Obstetrics / Gynecology: Estrogen Hormonal Contraceptives

Clinical manifestation: Birth control

Drug prescription: Estrogen hormonal contraceptives

Gene involved: *F5* (rs6025)

Phenotype: Increased risk of thrombosis

Standard risk
of thrombosis


**Standard
prescription**

Moderate risk
of thrombosis

Alternative agent

High risk of
thrombosis

Alternative agent



Oncology: Tamoxifen

Clinical manifestation: Breast cancer

Drug prescription: Tamoxifen

Gene involved: *CYP2D6* *1/*1x2

Phenotype: Ultrarapid metabolizer

Poor metabolizer
Risk of therapeutic failure


Alternative agent

Normal metabolizer

Label dosage

Ultrarapid metabolizer

Label dosage



Endocrinology: Allopurinol

Clinical manifestation: Acute episode of gout

Drug prescription: Allopurinol

Gene involved: *HLA-B* *58:01

Phenotype: Drug hypersensitivity (Stevens-Johnson syndrome)

Absence of risk variant

Standard prescription

Presence of risk variant

Alternative agent



Cardiology: Simvastatin

Clinical manifestation: High LDL-cholesterol

Drug prescription: Simvastatin

Gene involved: *SLCO1B1* *1/*15

Phenotype: Reduced activity (Statin-Associated Myopathy)

Reduced activity
Higher risk of myopathy

Alternative agent

Normal activity

Label dosage

Increased activity

Label dosage

Medical areas / Drugs



Cardiovascular

Atorvastatin, Clopidogrel, Flecainide, Fluvastatin, Hydralazine, Lovastatin, Metoprolol, Pitavastatin, Pravastatin, Propafenone, Rosuvastatin, Simvastatin



Endocrinology

Allopurinol, Eliglustat, Pegloticase, Toluidine blue



Gastroenterology

Dexlansoprazole, Lansoprazole, Metoclopramide, Omeprazole, Ondansetron, Pantoprazole, Tolterodine, Tropisetron



Hematology

Acenocoumarol, Clopidogrel, Methylene blue, Phenprocoumon, Warfarin



Infectious Diseases & Immune Disorders

Abacavir, Amikacin, Atazanavir, Azathioprine, Dapsone, Dibekacin, Efavirenz, Flucloxacillin, Gentamicin, Isoniazid, Kanamycin, Neomycin, Netilmicin, Nevirapine, Paromomycin, Peginterferon alfa-2a, Peginterferon alfa-2b, Plazomicin, Primaquine, Ribostamycin, Streptomycin, Sulfamethoxazole / Trimethoprim, Tafenoquine, Tobramycin, Voriconazole



Neurology

Amifampridine, Carbamazepine, Clobazam, Deutetrabenazine, Dextromethorphan / Quinidine, Fosphenytoin, Lamotrigine, Oxcarbazepine, Phenytoin, Pitolisant, Siponimod, Tetrabenazine, Valbenazine



Obstetrics / Gynecology

Estrogen hormonal contraceptives



Oncology

Capecitabine, Dabrafenib, Fluorouracil, Irinotecan, Lapatinib, Mercaptopurine, Rasburicase, Sacituzumab govitecan-hziy, Tamoxifen, Tegafur, Thioguanine



Ophthalmology

Methazolamide



Pain Medicine

Articaine, Celecoxib, Codeine, Desflurane, Dihydrocodeine, Enflurane, Flurbiprofen, Halothane, Hydrocodone, Ibuprofen, Isoflurane, Lornoxicam, Meloxicam, Methoxyflurane, Oliceridine, Oxycodone, Piroxicam, Sevoflurane, Succinylcholine, Tenoxicam, Tramadol



Psychiatry

Amitriptyline, Aripiprazole, Atomoxetine, Brexpiprazole, Citalopram, Clomipramine, Clozapine, Desipramine, Dextromethorphan hydrobromide / Bupropion hydrochloride, Doxepin, Escitalopram, Fluvoxamine, Haloperidol, Iloperidone, Imipramine, Methadone, Nortriptyline, Paroxetine, Pimozide, Quetiapine, Risperidone, Sertraline, Thioridazine, Trimipramine, Venlafaxine, Vortioxetine, Zuclopenthixol



Pulmonology

Salmeterol



Transplantation Medicine

Azathioprine, Tacrolimus

About Veritas

Veritas Genetics, a *LetsGetChecked* company, is a global leader in advanced genetic sequencing and the clinical interpretation of the whole exome and genome, driving the transition toward personalized and preventive medicine.

Leveraging state-of-the-art technology and the highest security standards, Veritas Genetics empowers individuals, healthcare professionals, and institutions worldwide to understand and anticipate genetic risks, enabling more informed and proactive health decisions.

Focused on innovation and accessibility, Veritas Genetics is transforming the way we understand and manage health throughout all stages of life.

Veritas technology allows the re-analysis of the genetic data to perform additional WES based tests or future pharmacogenomics updates under better conditions.



info@veritasint.com | veritasint.com

